Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
| ▸ | SKP1 | P63208 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 2/20 | 0.40 |
| ▸ | SUV39H2 | Q9H5I1 | 3/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | KDM4D | Q6B0I6 | 3/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14328869 | 0.85 | USP30 (0.46) | USP30CKS1BSKP1SKP2SUV39H2 | |
| SCHEMBL19297588 | 0.85 | USP30 (0.51) | USP30CKS1BSKP1SKP2SUV39H2 | |
| SCHEMBL25169776 | 0.83 | USP30 (0.54) | USP30CKS1BSKP1SKP2PRMT5 | |
| SCHEMBL902176 | 0.81 | GPR119 (0.47) | USP30CKS1BSKP1SKP2MET | |
| SCHEMBL3025640 | 0.80 | USP30 (0.58) | USP30CKS1BSKP1SKP2SUV39H2 | |
| SCHEMBL30124364 | 0.80 | PRMT5 (0.39) | USP30PRMT5WDR77 | |
| SCHEMBL8510780 | 0.79 | CKS1B (0.49) | CKS1BSKP1SKP2METSUV39H2 | |
| SCHEMBL3280488 | 0.77 | CKS1B (0.48) | CKS1BSKP1SKP2METSUV39H2 | |
| SCHEMBL29008842 | 0.77 | USP30 (0.61) | USP30CKS1BSKP1SKP2SUV39H2 | |
| SCHEMBL29339847 | 0.77 | USP30 (0.61) | USP30CKS1BSKP1SKP2SUV39H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850239-B2 | Pyrazolo[3,4-c]pyridine compounds and methods of use | GENENTECH, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850239-B2 | Pyrazolo[3,4-c]pyridine compounds and methods of use | GENENTECH, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160159797-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160159797-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-9260425-B2 | Pyrazolo[3,4-c]pyridine compounds and methods of use | GENETECH, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2796456-A1 | Bicyclic compounds as Pim inhibitors | Amgen Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| EP-2796456-A1 | Bicyclic compounds as Pim inhibitors | Amgen Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| EP-2742046-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-06-18 | — | — | EP | disclosed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2649065-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2013024002-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-21 | — | — | WO | disclosed |
| US-20130039906-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | US | disclosed |
| US-20130039906-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | US | disclosed |
| WO-2012078777-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012078777-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130039906-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | PIM1, PIM3, PIM2 | USP30 4610/4885CKS1B 67/4885SKP1 400/4885 |
| US-20160159797-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | PIM1, PIM3, PIM2 | USP30 4610/4885CKS1B 67/4885SKP1 400/4885 |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | PIM1, PIM2, PIM3 | USP30 3521/4885CKS1B 342/4885SKP1 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.